Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 3, 2012, Pages

  Holtzman, David M ^a   Herz, Joachim ^b   Bu, Guojun ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; N METHYL DEXTRO ASPARTIC ACID; REELIN; TAU PROTEIN; CARRIER PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELL FUNCTION; CENTRAL NERVOUS SYSTEM FUNCTION; DENDRITIC SPINE; ENDOCYTOSIS; GENETIC CORRELATION; GENOTYPE; GLIA CELL; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN TRANSPORT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; CARRIER PROTEINS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; NEURONAL PLASTICITY; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TRANSPORT;

EID: 84863504256     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006312     Document Type: Article

References (223)

1. Aleshkov S, Abraham CR, Zannis VI. 1997. Interaction of nascent apoE2, apoE3, and apoE4 isoforms expressed in mammalian cells with amyloid peptide β(1-40). Relevance to Alzheimer's disease. Biochemistry 36: 10571-10580.
2. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, et al. 2005. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. In Proc Natl Acad Sci 102: 13461-13466.
3. Anderson R, Barnes JC, Bliss TV, Cain DP, Cambon K, Davies HA, Errington ML, Fellows LA, Gray RA, Hoh T, et al. 1998. Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience 85: 93-110.
4. Arnaud L, Ballif BA, Forster E, Cooper JA. 2003. Fyn tyrosine kinase is a critical regulator of disabled-1 during brain development. Curr Biol 13: 9-17.
5. Assadi AH, Zhang G, Beffert U, McNeil RS, Renfro AL, Niu S, Quattrocchi CC, Antalffy BA, Sheldon M, Armstrong DD, et al. 2003. Interaction of reelin signaling and Lis1 in brain development. Nat Genet 35: 270-276.
6. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, JohnstoneEM, Little SP, Cummins DJ, et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17: 263-264.
7. Bales KR, Verina T, Cummins DJ, Du Y, Dodel JC, Saura J, Fishman CE, DeLongCA, Piccardo P, Petegnief V, et al. 1999. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci 96: 15233-15238.
8. Beffert U, Arguin C, Poirier J. 1999. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease. Neurosci Lett 259: 29-32.
9. Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J, Poirier J. 1998. β-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J Neurochem 70: 1458-1466.
10. Beffert U, Morfini G, Bock HH, Reyna H, Brady ST, Herz J. 2002. Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3β. J Biol Chem 277: 49958-49964.
11. Beffert U, Weeber EJ, Durudas A, Qiu S, Masiulis I, Sweatt JD, Li WP, AdelmannG, Frotscher M, Hammer RE, et al. 2005. Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron 47: 567-579.
12. Beffert U, Durudas A, Weeber EJ, Stolt PC, Giehl KM, Sweatt JD, Hammer RE, Herz J. 2006a. Functional dissection of Reelin signaling by site-directed disruption of Disabled-1 adaptor binding to apolipoprotein E receptor 2: Distinct roles in development and synaptic plasticity. J Neurosci 26: 2041-2052.
13. Beffert U, Nematollah Farsian F, Masiulis I, Hammer RE, Yoon SO, Giehl KM, Herz J. 2006b. ApoE receptor 2 controls neuronal survival in the adult brain. Curr Biol 16: 2446-2452.
14. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV. 2007. Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27: 909-918.
15. Benjamin R, Leake A, Ince PG, Perry RH, McKeith IG, Edwardson JA, Morris CM. 1995. Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Neurodegeneration 4: 443-448.
16. Berman DE, Dall'Armi C, Voronov SV, McIntire LB, Zhang H, Moore AZ, Staniszewski A, Arancio O, Kim TW, Di Paolo G. 2008. Oligomeric amyloid-β peptide disrupts phosphatidylinositol-4, 5-bisphosphate metabolism. Nat Neurosci 11: 547-554.
17. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet 39: 17-23.
18. Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM. 2005. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45: 675-688.
19. Bock HH, Herz J. 2003. Reelin activates SRC family tyrosine kinases in neurons. Curr Biol 13: 18-26.
20. Borrell V, Pujadas L, Simo S, Dura D, Sole M, Cooper JA, Del Rio JA, Soriano E. 2007. Reelin and mDab1 regulate the development of hippocampal connections. Mol Cell Neurosci 36: 158-173.
21. Boucher P, Liu P, Gotthardt M, Hiesberger T, Anderson RG, Herz J. 2002. Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae. J Biol Chem 277: 15507-15513.
22. Boycott KM, Flavelle S, Bureau A, Glass HC, Fujiwara TM, Wirrell E, Davey K, Chudley AE, Scott JN, McLeod DR, et al. 2005. Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification. Am J Human Genet 77: 477-483.
23. Boycott KM, Bonnemann C, Herz J, Neuert S, Beaulieu C, Scott JN, Venkatasubramanian A, Parboosingh JS. 2009. Mutations in VLDLR as a cause for autosomal recessive cerebellar ataxia with mental retardation (dysequilibrium syndrome). J Child Neurol 24: 1310-1315.
24. Brich J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, Jin LW, Mumby M, Churchill G, Herz J, et al. 2003. Genetic modulation of tau phosphorylation in the mouse. J Neurosci 23: 187-192.
25. Bu G. 2009. Apolipoprotein E and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy. Nat Rev Neurosci 10: 333-344.
26. Burk RF, Hill KE, Olson GE, Weeber EJ, Motley AK, Winfrey VP, Austin LM. 2007. Deletion of apolipoprotein E receptor-2 in mice lowers brain selenium and causes severe neurological dysfunction and death when a low-selenium diet is fed. J Neurosci 27: 6207-6211.
27. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G. 2004. The low density lipoprotein receptor-related protein 1B retains β-amyloid precursor protein at the cell surface and reduces amyloid-β peptide production. J Biol Chem 279: 29639-29646.
28. Cam JA, Zerbinatti CV, Li Y, Bu G. 2005. Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the β-amyloid precursor protein. J Biol Chem 280: 15464-15470.
29. Campo CG, Sinagra M, Verrier D, Manzoni OJ, Chavis P. 2009. Reelin secreted by GABAergic neurons regulates glutamate receptor homeostasis. PLoS One 4: e5505. doi: 10. 1371/journal. pone. 0005505.
30. Cao D, Fukuchi K, Wan H, Kim H, Li L. 2006. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging 27: 1632-1643.
31. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. 1995. Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E. Biochem J 306: 599-604.
32. Castellano JM, Kim J, Stewart FR, DeMattos RB, Patterson BW, Fagan AM, MorrisJC, Mawuenyega KG, Paul SM, Bateman RJ, et al. 2011. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3: 89ra57.
33. Chai X, Forster E, Zhao S, Bock HH, Frotscher M. 2009. Reelin acts as a stop signal for radially migrating neurons by inducing phosphorylation of n-cofilin at the leading edge. Commun Integr Biol 2: 375-377.
34. Chameau P, Inta D, Vitalis T, Monyer H, Wadman WJ, van Hooft JA. 2009. The N-terminal region of reelin regulates postnatal dendritic maturation of cortical pyramidal neurons. Proc Natl Acad Sci 106: 7227-7232.
35. Chen Y, Beffert U, Ertunc M, Tang TS, Kavalali ET, Bezprozvanny I, Herz J. 2005. Reelin modulates NMDA receptor activity in cortical neurons. J Neurosci 25: 8209-8216.
36. Chen Y, Durakoglugil MS, Xian X, Herz J. 2010. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci 107: 12011-12016.
37. Chin J, Massaro CM, Palop JJ, Thwin MT, Yu GQ, Bien-Ly N, Bender A, Mucke L. 2007. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J Neurosci 27: 2727-2733.
38. Chiu-Ugalde J, Theilig F, Behrends T, Drebes J, Sieland C, Subbarayal P, KohrleJ, Hammes A, Schomburg L, Schweizer U. 2010. Mutation of megalin leads to urinary loss of selenoprotein P and selenium deficiency in serum, liver, kidneys and brain. Biochem J 431: 103-111.
39. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, et al. 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 115: 3285-3290.
40. Cole GM, Ard MD. 2000. Influence of lipoproteins on microglial degradation of Alzheimer's amyloid β-protein. Microsc Res Tech 50: 316-324.
41. Cole SL, Vassar R. 2007. The Alzheimer's disease β-secretase enzyme, BACE1. Mol Neurodegener 2: 22.
42. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
43. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PCJr., Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. 1994. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7: 180-184.
44. Costa E, Davis J, Grayson DR, Guidotti A, Pappas GD, Pesold C. 2001. Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis 8: 723-742.
45. D'Arcangelo G. 2005. Apoer 2: A reelin receptor to remember. Neuron 47: 471-473.
46. D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. 1999. Reelin is a ligand for lipoprotein receptors. Neuron 24: 471-479.
47. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, et al. 2004. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43: 333-344.
48. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, ZlokovicBV. 2008. apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest 118: 4002-4013.
49. De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Saez K, Henriquez JP, Zhao A, et al. 2007. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci 104: 9434-9439.
50. Del Rio JA, Heimrich B, Borrell V, Forster E, Drakew A, Alcantara S, Nakajima K, Miyata T, Ogawa M, Mikoshiba K, et al. 1997. A role for Cajal-Retzius cells and reelin in the development of hippocampal connections. Nature 385: 70-74.
51. DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer JD, SullivanPM, Fagan AM, Han X, Holtzman DM. 2001. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int 39: 415-425.
52. DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JAK, Bales KR, Paul SM, Aronow BJ, Holtzman DM. 2002. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci 10: 10843-10848.
53. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JM, Harmony JAK, Aronow BJ, Bales KR, Paul SM, et al. 2004. ApoE and clusterin cooperatively suppress Ab levels and deposition: Evidence that apoE regulates extracellular Ab metabolism in vivo. Neuron 41: 193-202.
54. Dieckmann M, Dietrich MF, Herz J. 2010. Lipoprotein receptors-An evolutionarily ancient multifunctional receptor family. Biol Chem 391: 1341-1363.
55. Dietrich MF, van der Weyden L, Prosser HM, Bradley A, Herz J, Adams DJ. 2010. Ectodomains of the LDL receptor-related proteins LRP1b and LRP4 have anchorage independent functions in vivo. PLoS One 5: e9960. doi: 10. 1371/journal. pone. 0009960.
56. Dillon C, Goda Y. 2005. The actin cytoskeleton: Integrating form and function at the synapse. Annu Rev Neurosci 28: 25-55.
57. Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, WeeberEJ, Turner RS, Xu B, Rebeck GW, et al. 2009. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 29: 15317-15322.
58. Durakoglugil MS, Chen Y, White CL, Kavalali ET, Herz J. 2009. Reelin signaling antagonizes β-amyloid at the synapse. Proc Natl Acad Sci 106: 15938-15943.
59. Evans KC, Berger EP, Cho C-G, Weisgraber KH, Lansbury PT. 1994. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci 92: 763-767.
60. Fagan AM, Bu G, Sun Y, Daugherty A, Holtzman DM. 1996. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 271: 30121-30125.
61. -/- mice but impaired clearance of axonal degeneration products following injury. Exp Neurol 151: 314-325.
62. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. 2002. Human and murine apoE markedly influence Aβ metabolism both prior and subsequent to plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9: 305-318.
63. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349-1356.
64. Forster E, Bock HH, Herz J, Chai X, Frotscher M, Zhao S. 2010. Emerging topics in Reelin function. Eur J Neurosci 31: 1511-1518.
65. Frotscher M. 2010. Role for Reelin in stabilizing cortical architecture. Trends Neurosci 33: 407-414.
66. Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, HoltzmanDM. 2003. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in APP transgenic mice. J Neurosci 23: 7889-7896.
67. Fryer JD, Demattos RB, McCormick LM, O'Dell M A, Spinner ML, Bales KR, PaulSM, Sullivan PM, Parsadanian M, Bu G, et al. 2005a. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem 280: 25754-25759.
68. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, HoltzmanDM. 2005b. ApoE4 alters the amyloid-β 40: 42 ratio and promotes the formation of cerebral amyloid angiopathy in an APP transgenic model. J Neurosci 25: 2803-2810.
69. Fuentealba RA, Barria MI, Lee J, Cam J, Araya C, Escudero CA, Inestrosa NC, Bronfman FC, Bu G, Marzolo MP. 2007. ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity. Mol Neurodegener 2: 14.
70. Gajera CR, Emich H, Lioubinski O, Christ A, Beckervordersandforth-Bonk R, Yoshikawa K, Bachmann S, Christensen EI, Gotz M, Kempermann G, et al. 2010. LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche. J Cell Sci 123: 1922-1930.
71. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM. 2010. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 30: 6367-6374.
72. Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, YanagisawaK, Michikawa M. 2002. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem 277: 29919-29926.
73. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, StockingerW, Nimpf J, Herz J. 2000. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem 275: 25616-25624.
74. Greenberg SM, Rebeck GW, Vonsattel JPG, Gomez-Isla T, Hyman BT. 1995. Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38: 254-259.
75. Grehan S, Tse E, Taylor JM. 2001. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci 21: 812-822.
76. Groc L, Choquet D, Stephenson FA, Verrier D, Manzoni OJ, Chavis P. 2007. NMDA receptor surface trafficking and synaptic subunit composition are developmentally regulated by the extracellular matrix protein Reelin. J Neurosci 27: 10165-10175.
77. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8: 101-112.
78. Haass C, Kaether C, Sisodia S, Thinakaran G. 2011. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006270.
79. Han X. 2007. Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: A tale of shotgun lipidomics. J Neurochem 103: 171-179.
80. Hardingham GE, Fukunaga Y, Bading H. 2002. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5: 405-414.
81. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, PahwaJS, Moskvina V, Dowzell K, Williams A, et al. 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093.
82. Heinonen O, Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Sorvari H, Kosunen O, Paljarvi L, Ryynanen M, Riekkinen PJ Sr. 1995. Alzheimer pathology of patients carrying apolipoprotein E ε4 allele. Neurobiol Aging 16: 505-513.
83. Herz J. 2009. Apolipoprotein E receptors in the nervous system. Curr Opin Lipidol 20: 190-196.
84. Herz J, Beffert U. 2000. Apolipoprotein E receptors: Linking brain development and Alzheimer's disease. Nature Rev 1: 51-58.
85. Herz J, Chen Y. 2006. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 7: 850-859.
86. Herz J, Clouthier DE, Hammer RE. 1992. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71: 411-421.
87. Herz J, Chen Y, Masiulis I, Zhou L. 2009. Expanding functions of lipoprotein receptors. J Lipid Res 50(Suppl): S287-S292.
88. Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, Herz J. 1999. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron 24: 481-489.
89. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. 2004. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279: 41197-41207.
90. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, et al. 2005. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem 280: 43243-43256.
91. Hoe HS, Wessner D, Beffert U, Becker AG, Matsuoka Y, Rebeck GW. 2005. F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Mol Cell Biol 25: 9259-9268.
92. Hoe HS, Freeman J, Rebeck GW. 2006a. Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons. Mol Neurodegen 1: 18.
93. Hoe HS, Pocivavsek A, Chakraborty G, Fu Z, Vicini S, Ehlers MD, Rebeck GW. 2006b. Apolipoprotein E receptor 2 interactions with the N-methyl-D-aspartate receptor. J Biol Chem 281: 3425-3431.
94. Hoe HS, Fu Z, Makarova A, Lee JY, Lu C, Feng L, Pajoohesh-Ganji A, MatsuokaY, Hyman BT, Ehlers MD, et al. 2009. The effects of amyloid precursor protein on postsynaptic composition and activity. J Biol Chem 284: 8495-8506.
95. Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, Bu G, Schwartz AL. 1995. LRP mediates apolipoprotein E-dependent neurite outgrowth in a CNS-derived neuronal cell line. Proc Natl Acad Sci 92: 9480-9484.
96. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, et al. 2000a. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci 97: 2892-2897.
97. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizzary MC, Hyman BT. 2000b. ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease. Ann Neurol 47: 739-747.
98. Hone E, Martins IJ, Jeoung M, Ji TH, Gandy SE, Martins RN. 2005. Alzheimer's disease amyloid-β peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis 7: 303-314.
99. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, et al. 2010. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68: 1067-1081.
100. Howell BW, Gertler FB, Cooper JA. 1997. Mouse disabled (mDab1): A Src binding protein implicated in neuronal development. EMBO J 16: 121-132.
101. Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee JM. 2009. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-β peptide. Proc Natl Acad Sci 106: 20324-20329.
102. Huang SS, Ling TY, Tseng WF, Huang YH, Tang FM, Leal SM, Huang JS. 2003. Cellular growth inhibition by IGFBP-3 and TGF-β1 requires LRP-1. FASEB J 17: 2068-2081.
103. Irizarry MC, Cheung BS, Rebeck GW, Paul SM, Bales KR, Hyman BT. 2000. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid β-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol 100: 451-458.
104. Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T. 2007. Cerebral clearance of human amyloid-β peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J Neurochem 103: 2482-2490.
105. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, ChiengBC, Christie MJ, Napier IA, et al. 2010. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142: 387-397.
106. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, LambB, Willson TM, Collins JL, et al. 2008. ApoE promotes the proteolytic degradation of Aβ. Neuron 58: 681-693.
107. Johnson EB, Hammer RE, Herz J. 2005. Abnormal development of the apical ectodermal ridge and polysyndactyly in Megf7-deficient mice. Hum Mol Genet 14: 3523-3538.
108. Kanekiyo T, Bu G. 2009. Receptor-associated protein interacts with amyloid-β peptide and promotes its cellular uptake. J Biol Chem 284: 33352-33359.
109. Karner CM, Dietrich MF, Johnson EB, Kappesser N, Tennert C, Percin F, WollnikB, Carroll TJ, Herz J. 2010. Lrp4 regulates initiation of ureteric budding and is crucial for kidney formation-A mouse model for Cenani-Lenz syndrome. PLoS One 5: e10418. doi: 10. 1371/journal. pone. 0010418.
110. Kim J, Basak JM, Holtzman DM. 2009a. The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287-303.
111. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. 2009b. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance. Neuron 64: 632-644.
112. Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck GW, Strickland DK, Hyman BT. 2001. Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: Role of the intracellular adapter protein Fe65. J Neurosci 21: 8354-8361.
113. Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I. 2010. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. J Neurosci 30: 9228-9240.
114. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, et al. 2004. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat Med 10: 719-726.
115. Koldamova R, Staufenbiel M, Lefterov I. 2005a. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280: 43224-43235.
116. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. 2005b. The liver X receptor ligand T0901317 decreases amyloid β production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 280: 4079-4088.
117. Korwek KM, Trotter JH, Ladu MJ, Sullivan PM, Weeber EJ. 2009. ApoE isoform-dependent changes in hippocampal synaptic function. Molec Neurodegen 4: 21.
118. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. 1995. LDL-receptor-related protein, a multifunctional apoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation. Cell 82: 331-340.
119. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. 1990. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 265: 10771-10779.
120. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, et al. 2004. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24: 10191-10200.
121. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. 1994. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 269: 23404-23406.
122. LaDu MJ, Gilligan SM, Lukens SR, Cabana VG, Reardon CA, Van Eldik LJ, Holtzman DM. 1998. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem 70: 2070-2081.
123. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, MorganTE, Rozovsky I, Trommer B, Viola KL, et al. 1998. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci 95: 6448-6453.
124. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, CombarrosO, Zelenika D, Bullido MJ, Tavernier B, et al. 2009. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099.
125. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, AsheKH. 2006. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352-357.
126. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. 2008. LDL receptor-related protein 1: Unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 88: 887-918.
127. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G. 2007. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56: 66-78.
128. Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D, Ulery PG, Mikhailenko I, Lawrence DA, Strickland DK. 2002. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF. J Biol Chem 277: 15499-15506.
129. Ma J, Yee A, Brewer HB, Das S, Potter H. 1994. Amyloid-associated proteins α-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372: 92-94.
130. Mahley RW. 1988. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240: 622-630.
131. Mahley RW, Rall SC Jr. 2000. Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537.
132. Mahley RW, Huang Y, Weisgraber KH. 2006. Putting cholesterol in its place: ApoE and reverse cholesterol transport. J Clin Invest 116: 1226-1229.
133. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. 2009. Microglia mediate the clearance of soluble Aβ through fluid phase macropinocytosis. J Neurosci 29: 4252-4262.
134. Masiulis I, Quill TA, Burk RF, Herz J. 2009. Differential functions of the Apoer2 intracellular domain in selenium uptake and cell signaling. Biol Chem 390: 67-73.
135. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. 1995. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 136: 107-122.
136. Matsuki T, Pramatarova A, Howell BW. 2008. Reduction of Crk and CrkL expression blocks reelin-induced dendritogenesis. J Cell Sci 121: 1869-1875.
137. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW. 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357.
138. May P, Rohlmann A, Bock HH, Zurhove K, Marth JD, Schomburg ED, Noebels JL, Beffert U, Sweatt JD, Weeber EJ, et al. 2004. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol 24: 8872-8883.
139. McLaughlin L, Zhu G, Mistry M, Ley-Ebert C, Stuart WD, Florio CJ, Groen PA, Witt SA, Kimball TR, Witte DP, et al. 2000. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J Clin Invest 106: 1105-1113.
140. Michikawa M, Fan QW, Isobe I, Yanagisawa K. 2000. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74: 1008-1016.
141. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. 2010. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131.
142. Mucke L, Selkoe DJ. 2011. Neurotoxicity of amyloid β-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006338.
143. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, et al. 2004. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9: 522-530.
144. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res 541: 163-166.
145. 2-Macroglobulin complexes with and mediates the endocytosis of β-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem 69: 1904-1911.
146. Narita M, Holtzman DM, Fagan AM, LaDu MJ, Yu L, Han X, Gross RW, Bu G, Schwartz AL. 2002. Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein. J Biochem 132: 743-749.
147. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. 1994. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264: 850-852.
148. Nickerson DA, Taylor SL, Fullerton SM, Weiss KM, Clark AG, Stengard JH, Salomaa V, Boerwinkle E, Sing CF. 2000. Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res 10: 1532-1545.
149. Niu S, Renfro A, Quattrocchi CC, Sheldon M, D'Arcangelo G. 2004. Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway. Neuron 41: 71-84.
150. Niu S, Yabut O, D'Arcangelo G. 2008. The Reelin signaling pathway promotes dendritic spine development in hippocampal neurons. J Neurosci 28: 10339-10348.
151. Nygaard HB, Strittmatter SM. 2009. Cellular prion protein mediates the toxicity of β-amyloid oligomers: Implications for Alzheimer disease. Arch Neurol 66: 1325-1328.
152. Ohkubo N, Lee YD, Morishima A, Terashima T, Kikkawa S, Tohyama M, Sakanaka M, Tanaka J, Maeda N, Vitek MP, et al. 2003. Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3β cascade. FASEB J 17: 295-297.
153. Palop JJ, Mucke L. 2010. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks. Nat Neurosci 13: 812-818.
154. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, YuGQ, Kreitzer A, et al. 2007. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697-711.
155. Peters MM, Hill KE, Burk RF, Weeber EJ. 2006. Altered hippocampus synaptic function in selenoprotein P deficient mice. Mol Neurodegener 1: 12.
156. Pfrieger FW. 2003. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 60: 1158-1171.
157. Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. 2004. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 24: 4259-4265.
158. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. 1987. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917: 148-161.
159. Poirier J. 2003. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 9: 94-101.
160. Pujadas L, Gruart A, Bosch C, Delgado L, Teixeira CM, Rossi D, de Lecea L, Martinez A, Delgado-Garcia JM, Soriano E. 2010. Reelin regulates postnatal neurogenesis and enhances spine hypertrophy and long-term potentiation. J Neurosci 30: 4636-4649.
161. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O. 2008. Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28: 14537-14545.
162. Qiu S, Zhao LF, Korwek KM, Weeber EJ. 2006. Differential reelin-induced enhancement of NMDA and AMPA receptor activity in the adult hippocampus. J Neurosci 26: 12943-12955.
163. Rapp A, Gmeiner B, Huttinger M. 2006. Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88: 473-483.
164. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. 1993. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11: 575-580.
165. Rebeck GW, Harr SD, Strickland DK, Hyman BT. 1995. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein receptor, the α2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 37: 211-217.
166. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, et al. 2009. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci 106: 6820-6825.
167. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A. 2010. Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for mGluR5. Neuron 66: 739-754.
168. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, YuGQ, Mucke L. 2007. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.
169. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, et al. 2011. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31: 700-711.
170. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, et al. 2007. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39: 168-177.
171. Ronicke R, Mikhaylova M, Ronicke S, Meinhardt J, Schroder UH, Fandrich M, Reiser G, Kreutz MR, Reymann KG. 2010. Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol Aging doi: 10. 1016/j. neurobiolaging. 2010. 01. 011.
172. Rust MB, Gurniak CB, Renner M, Vara H, Morando L, Gorlich A, Sassoe-Pognetto M, Banchaabouchi MA, Giustetto M, Triller A, et al. 2010. Learning, AMPA receptor mobility and synaptic plasticity depend on n-cofilin-mediated actin dynamics. EMBO J 29: 1889-1902.
173. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T. 2006. Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci 103: 18787-18792.
174. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, et al. 2007. Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med 13: 1029-1031.
175. Saido T, Leissring MA. 2011. Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med doi: 10. 1011/cshperspect. a006379.
176. Salter MW, Kalia LV. 2004. Src kinases: A hub for NMDA receptor regulation. Nat Rev Neurosci 5: 317-328.
177. Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860-869.
178. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr. 1982. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2: 16-26.
179. Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, BujoH, Levey AI, Lah JJ. 2004. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 61: 1200-1205.
180. Schmechel DE, Saunders AM, Strittmattter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. 1993. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein genotype in late-onset Alzheimer disease. Proc Natl Acad Sci 90: 9649-9653.
181. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875.
182. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, BrettFM, Farrell MA, Rowan MJ, Lemere CA, et al. 2008. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
183. Sheldon M, Rice DS, D'Arcangelo G, Yoneshima H, Nakajima K, Mikoshiba K, Howell BW, Cooper JA, Goldowitz D, Curran T. 1997. Scrambler and yotari disrupt the disabled gene and produce a reeler-like phenotype in mice. Nature 389: 730-733.
184. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, HoltzmanDM, Miller CA, Strickland DK, Ghiso J, et al. 2000. Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106: 1489-1499.
185. Shu T, Ayala R, Nguyen MD, Xie Z, Gleeson JG, Tsai LH. 2004. Ndel1 operates in a common pathway with LIS1 and cytoplasmic dynein to regulate cortical neuronal positioning. Neuron 44: 263-277.
186. Sinagra M, Verrier D, Frankova D, Korwek KM, Blahos J, Weeber EJ, Manzoni OJ, Chavis P. 2005. Reelin, very-low-density lipoprotein receptor, and apolipoprotein E receptor 2 control somatic NMDA receptor composition during hippocampal maturation in vitro. J Neurosci 25: 6127-6136.
187. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, SalterMW, Lombroso PJ, Gouras GK, et al. 2005. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8: 1051-1058.
188. Sorci-Thomas M, Prack MM, Dashti N, Johnson F, Rudel LL, Williams DL. 1988. Apolipoprotein (apo) A-I production and mRNA abundance explain plasma apoA-I and high density lipoprotein differences between two nonhuman primate species with high and low susceptibilities to diet-induced hypercholesterolemia. J Biol Chem 263: 5183-5189.
189. Stockinger W, Brandes C, Fasching D, Hermann M, Gotthardt M, Herz J, Schneider WJ, Nimpf J. 2000. The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and-2. J Biol Chem 275: 25625-25632.
190. Stolt PC, Chen Y, Liu P, Bock HH, Blacklow SC, Herz J. 2005. Phosphoinositide binding by the disabled-1 PTB domain is necessary for membrane localization and Reelin signal transduction. J Biol Chem 280: 9671-9677.
191. Strasser V, Fasching D, Hauser C, Mayer H, Bock HH, Hiesberger T, Herz J, Weeber EJ, Sweatt JD, Pramatarova A, et al. 2004. Receptor clustering is involved in Reelin signaling. Mol Cell Biol 24: 1378-1386.
192. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993a. Apolipoprotein E: High avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90: 1977-1981.
193. Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-Y, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. 1993b. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci 90: 8098-8102.
194. 1-42and tau in control subjects at risk for Alzheimer's disease: The effect of APOE ε4 allele. Biol Psychiatry 56: 670-676.
195. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, DrexlerD, Zhou L, Rune G, Mandelkow E, et al. 2011. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant. J Neurosci 31: 2511-2525.
196. Tamamizu-Kato S, Cohen JK, Drake CB, Kosaraju MG, Drury J, NarayanaswamiV. 2008. Interaction with amyloid β peptide compromises the lipid binding function of apolipoprotein E. Biochemistry 47: 5225-5234.
197. Terrand J, Bruban V, Zhou L, Gong W, El Asmar Z, May P, Zurhove K, Haffner P, Philippe C, Woldt E, et al. 2009. LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J Biol Chem 284: 381-388.
198. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. 2004. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62: 1977-1983.
199. Tissir F, Goffinet AM. 2003. Reelin and brain development. Nat Rev Neurosci 4: 496-505.
200. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, et al. 2000. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides. Biochem J 348: 359-365.
201. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. 2006. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: A potent role for trimers. J Physiol 572: 477-492.
202. Trommsdorff M, Borg JP, Margolis B, Herz J. 1998. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem 273: 33556-33560.
203. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. 1999. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 97: 689-701.
204. Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, StricklandDK. 2000. Modulation of β-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem 275: 7410-7415.
205. Van Uden E, Mallory M, Ieinbergs I, Alford M, Rockenstein E, Masliah E. 2002. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci 22: 9298-9304.
206. Vazquez-Higuera JL, Mateo I, Sanchez-Juan P, Rodriguez-Rodriguez E, PozuetaA, Infante J, Berciano J, Combarros O. 2009. Genetic interaction between tau and the apolipoprotein E receptor LRP1 Increases Alzheimer's disease risk. Dement Geriat Cogn Disord 28: 116-120.
207. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, HoltzmanDM. 2005. Deletion of Abca1 increases Aβ deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280: 43236-43242.
208. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, et al. 2008. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118: 671-682.
209. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
210. Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, Herz J. 2002. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem 277: 39944-39952.
211. Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, Burns DK, HerzJ. 1996. Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci 93: 8460-8464.
212. Wisniewski T, Frangione B. 1992. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135: 235-238.
213. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. 1994. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145: 1030-1035.
214. Wood SJ, Chan W, Wetzel R. 1996. Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35: 12623-12628.
215. Xu P-T, Schmechel D, Qiu H-L, Herbstreith M, Rothrock-Christian T, Eyster M, Roses AD, Gilbert JR. 1999. Sialylated human apolipoprotein E (apoEs) is preferentially associated with neuron-enriched cultures from APOE transgenic mice. Neurobiol Dis 6: 63-75.
216. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. 2006. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 26: 4985-4994.
217. Yang D-S, Smith JD, Zhou Z, Gandy S, Martins RN. 1997. Characterization of the binding of amyloid-β peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 68: 721-725.
218. Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN. 1999. Apolipoprotein E promotes the binding and uptake of β-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90: 1217-1226.
219. Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, Zhuo M, PaulSM, Holtzman DM, Bu G. 2004. Increased soluble amyloid-β peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci 101: 1075-1080.
220. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G. 2006. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Aβ42 accumulation in amyloid model mice. J Biol Chem 281: 36180-36186.
221. Zhuo M, Holtzman DM, Li Y, Osaka H, DeMaro J, Jacquin M, Bu G. 2000. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci 20: 542-549.
222. Zlokovic BV. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201.
223. Zurhove K, Nakajima C, Herz J, Bock HH, May P. 2008. γ-secretase limits the inflammatory response through the processing of LRP1. Sci Signal 1: ra15.